Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)

被引：0
|
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL 33407 USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study (vol 19, P5, 2018)
    Brandes, Jan L.
    Yeung, Paul P.
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [22] Efficacy of Long-Term Fremanezumab Treatment in Patients with Chronic or Episodic Migraine and Prior Inadequate Response to Multiple Migraine Preventive Medication Classes
    Naegel, Steffen
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Ning, Xiaoping
    Carr, Karen
    Kudrow, David
    ANNALS OF NEUROLOGY, 2021, 90 : S132 - S133
  • [23] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Results of a 1-Year Study
    Brandes, Jan
    Marmura, Michael
    Yeung, Paul
    Cohen, Joshua
    Gandhi, Sanjay
    Yang, Ronghua
    NEUROLOGY, 2019, 92 (15)
  • [24] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study
    Brandes, Jan L.
    Yeung, Paul P.
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [25] Progressive improvements in efficacy and disability with fremanezumab in patients with medication overuse and inadequate response to multiple migraine preventive medication classes
    Spierings, Egilius
    Campos, Verena Ramirez
    Barash, Steve
    Krasenbaum, Lynda
    Cohen, Joshua
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 213 - 213
  • [26] Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies
    Reuter, U.
    Schwedt, T.
    Kudrow, D.
    Paemeleire, K.
    Zhang, F.
    Klatt, J.
    Picard, H.
    Chou, D.
    Mikol, D. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 637 - 637
  • [27] Reduction in acute headache medication use with fremanezumab in chronic migraine patients by prior migraine preventive treatment use: Subgroup analysis of the HALO CM study
    Stark, R.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [28] Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication (vol 19, pg P8, 2018)
    Goadsby, Peter J.
    Dodick, David W.
    Silberstein, Stephen D.
    Yeung, Paul P.
    Blankenbiller, Tricia
    Ning, Xiaoping
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [29] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Lipton, R. B.
    Turner, I. M.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 114
  • [30] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Interim Results of a One-Year Study
    McAllister, P.
    Yeung, P. P.
    Cohen, J. M.
    Gandhi, S. K.
    Fitzgerald, T.
    Yang, R.
    Ma, Y.
    Aycardi, E.
    HEADACHE, 2018, 58 : 86 - 87
12345